Pharmaceutical

Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy

IGNYTE-3 is a Phase III trial investigating Replimune’s flagship oncolytic treatment for advanced, treatment-resistant melanoma.

Aug 15, 2024 - 04:00
Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy
IGNYTE-3 is a Phase III trial investigating Replimune’s flagship oncolytic treatment for advanced, treatment-resistant melanoma.
Read the original article

Tags:

Previous Article

CNIO researchers discover a ‘switch’ for the desire to engage in physical activi...

Next Article

Kezar stalls solid tumour trial to focus on autoimmune disease candidate

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Abortion policy in the spotlight, DeSantis’ importation showdown, and new price hike analysis

STAT+: Abortion policy in the spotlight, DeSantis’ impo...

Aug 27, 2023

NHS to provide Pfizer’s Voxelotor to treat sickle cell disease

NHS to provide Pfizer’s Voxelotor to treat sickle cell ...

May 5, 2024

JAMA’s new editor settles in, bringing open access and other changes

JAMA’s new editor settles in, bringing open access and ...

Mar 19, 2023